Phathom Fills 95 Patients in a Disease With No Approved PPI: What the pHalcon-EoE-201 Enrollment Speed Reveals

Picture the conversation a gastroenterologist has with an EoE patient every week: “We’re going to try a proton pump inhibitor.” The patient asks whether it’s FDA-approved for their condition. The physician pauses. Technically, no — not a single PPI carries an FDA approval for eosinophilic esophagitis, yet they function as the clinical standard of care across the United States, recommended by the American College of Gastroenterology as first-line therapy. That regulatory gap, sitting uncomfortably between clinical practice and labeling reality, is exactly the space Phathom Pharmaceuticals walked into when it designed the pHalcon-EoE-201 study.

On June 23, 2026, Phathom announced it had completed enrollment in its Phase 2 trial evaluating VOQUEZNA (vonoprazan) 20 mg once daily in adults with endoscopically confirmed EoE and dysphagia — ahead of schedule, 95 patients randomized across 41 U.S. sites. Topline results are expected in Q4 2026. The announcement was brief, as enrollment completion announcements usually are. But the operational reality underneath it deserves more scrutiny than a press release typically invites.

Early enrollment in a rare GI disease trial is not a footnote. It is a signal about site selection quality, patient identification pipelines, and protocol design tolerance — all of which will echo into the readout, for better or worse.

The Enrollment Signal Most Sponsors Miss

EoE affects approximately 1 in 700 Americans, according to a prevalence study published October 31, 2024, and delayed diagnosis is endemic to the condition. Symptoms — dysphagia, food impaction, chest pain — overlap with GERD and are frequently dismissed until a patient undergoes endoscopy. That diagnostic latency means identifying trial-eligible adults requires more than posting on ClinicalTrials.gov. It requires site teams who can systematically surface undiagnosed or recently diagnosed patients from endoscopy records, allergy clinics, and GI practices simultaneously.

Phathom enrolled 95 patients across 41 sites, which works out to an average of roughly 2.3 patients per site. That number carries a double reading. On one hand, it suggests broad geographic distribution — the kind of multi-site footprint that reduces selection bias and supports generalizability when topline results arrive. On the other hand, 2.3 patients per site in a 12-week randomized trial means most sites never built a deep operational rhythm with the protocol. The investigators who enrolled one patient and the ones who enrolled five had meaningfully different site experiences, and that variance can quietly introduce protocol execution inconsistency that no CRF catches.

The design itself made enrollment tractable. Part 1 is a clean 1:1 randomization to vonoprazan 20 mg or placebo for 12 weeks, with all completers rolling into a 12-week open-label extension in Part 2. There are no complex adaptive rules, no biomarker stratification layers, no interim futility analysis that could complicate site-level management. Phathom built a protocol that a gastroenterology practice could run without a dedicated subspecialty research infrastructure — and that choice almost certainly contributed to the ahead-of-schedule completion.

The Regulatory Gamble Hiding in Plain Sight

Here is the counterintuitive read on Phathom’s position: the very ubiquity of off-label PPI use in EoE is both the commercial opportunity and the evidentiary problem. Because gastroenterologists already prescribe acid suppression for EoE without a labeled indication, there has been no regulatory forcing function requiring anyone to run a large placebo-controlled trial. The ACG Clinical Guideline recommends PPIs as first-line therapy based on observational data and mechanistic rationale, not randomized controlled evidence. Phathom’s own press release describes pHalcon-EoE-201 as “the first large, placebo-controlled clinical trial of an acid suppression treatment in EoE.” Read that sentence twice. In 2026, this is still a first.

That context reframes what a positive Phase 2 result would actually mean. It would not simply validate vonoprazan in EoE — it would generate the first placebo-controlled efficacy signal for the entire acid suppression drug class in this indication. That is a regulatory event with implications well beyond Phathom’s pipeline. The FDA has never had to evaluate a sponsor’s NDA or sNDA for PPI use in EoE because no sponsor has ever brought one. If vonoprazan clears Phase 2 with a compelling histologic and symptomatic response profile, Phathom will be negotiating the regulatory pathway for a labeled acid suppression indication in EoE from scratch, without precedent to cite.

VOQUEZNA received FDA approval on November 1, 2023, for erosive GERD — the first major innovation in the U.S. erosive GERD market in over 30 years. Vonoprazan’s mechanism as a potassium-competitive acid blocker (PCAB) offers more rapid and sustained acid suppression than conventional PPIs, which require an acidic environment to activate and lose efficacy during nighttime acid breakthrough. That pharmacological profile matters in EoE because the inflammatory cascade is at least partially pH-dependent. Whether a more potent acid blocker produces a meaningfully better histologic outcome than a PPI would have produced is precisely the question pHalcon-EoE-201 cannot answer — because there is no approved PPI comparator arm to benchmark against. The trial compares vonoprazan to placebo, full stop.

That design choice is scientifically defensible given the absence of any approved acid suppression therapy in EoE. But it sets up an uncomfortable post-Phase-2 question: if vonoprazan shows efficacy versus placebo, how does the FDA evaluate the marginal benefit over the PPIs that 30 million Americans already take? Phathom will need an answer to that before any Phase 3 endpoints are locked.

What Q4 2026 Data Could Actually Move

The competitive landscape for EoE has shifted decisively since the trial was designed. Sanofi and Regeneron’s Dupixent (dupilumab) received FDA approval on January 25, 2024, for EoE in pediatric patients aged 1 to 11 years weighing at least 15 kg — making it the first biologic approved for EoE in that age group and cementing dupilumab’s position as the category-defining agent in the disease. Dupixent already holds adult EoE labeling. A potassium-competitive acid blocker is not going to displace a proven IL-4/IL-13 pathway inhibitor in patients with moderate-to-severe disease. But that comparison misses the actual patient population Phathom is targeting.

The real market is the EoE patient who presents to a community gastroenterologist, receives a PPI prescription written off-label with no FDA backing, and tolerates it reasonably well but wonders whether there is something better — or whether what they are taking is even supported by evidence. With EoE affecting roughly 1 in 700 Americans, that population is large enough to support a commercial launch, particularly if vonoprazan’s label carries efficacy language that off-label PPI use never could. Phathom projects net revenues of $320 million to $345 million for full-year 2026 from its existing GERD franchise, with a gross margin of approximately 80%, according to the company’s financial guidance. A labeled EoE indication would extend both the addressable market and, critically, the regulatory exclusivity runway — which is why Phathom’s press release explicitly flags pediatric evaluation as the next development step if Phase 2 succeeds.

Pediatric EoE is where the regulatory calculus gets sharper. FDA pediatric exclusivity grants a six-month extension to existing market exclusivity when a sponsor completes FDA-requested pediatric studies. For a PCAB with an 80% gross margin and a growing GERD base, six additional months of exclusivity is not a strategic nicety — it is a material revenue event. Phathom is building the adult Phase 2 data package now precisely because it needs that foundation before the FDA will engage meaningfully on a pediatric written request.

Which brings the operational question back to site execution. The 95-patient, 41-site footprint that completed enrollment ahead of schedule is not the infrastructure Phathom needs for a Phase 3 program. A pivotal EoE trial will require deeper site penetration, longer treatment windows, and a primary endpoint — likely eosinophil count per high-power field combined with a validated dysphagia symptom score — that demands more rigorous and consistent biopsy handling than a Phase 2 protocol typically enforces. Sponsors who recruit efficiently at Phase 2 by distributing patients thinly across many sites sometimes discover at Phase 3 that they built a mile-wide, inch-deep investigator network. The site teams who enrolled one or two vonoprazan patients in pHalcon-EoE-201 will need active re-engagement and retraining before they can anchor a registrational trial.

The topline readout coming in Q4 2026 will tell Phathom whether the science works. What the enrollment completion announced on June 23 already tells us is that the operational infrastructure can find EoE patients when the protocol is designed to let community gastroenterologists participate. The harder test — converting that broad enrollment footprint into a disciplined, Phase-3-ready site network — begins the morning after the data drop, not before.

References

1. GlobeNewswire / Phathom Pharmaceuticals — “Phathom Pharmaceuticals Completes Patient Enrollment Ahead of Schedule in Phase 2 pHalcon-EoE-201 Study of VOQUEZNA (vonoprazan) in Eosinophilic Esophagitis (EoE)”
2. AJMC — “FDA Approves Erosive GERD Therapy Vonoprazan”
3. PubMed — “Prevalence and Costs of Eosinophilic Esophagitis in the United States” (October 31, 2024)
4. American College of Gastroenterology — ACG Clinical Guideline: Eosinophilic Esophagitis
5. Sanofi — “FDA Approves Dupixent for Pediatric Patients with Eosinophilic Esophagitis” (January 25, 2024)
6. StockTitan / Phathom Pharmaceuticals — 2026 Financial Guidance and Pipeline Update